Case study
Real-world usage of anti-seizure medications
Understanding medication side effects
The relationship between epilepsy, anti-seizure medications (ASMs), and cardiac comorbidities is complex. Individuals with epilepsy may have a higher risk of developing arrhythmias, and emerging research suggests certain ASMs could contribute to this risk. The FDA recently issued a Drug Safety Communication for lamotrigine, warning of potential proarrhythmic effects based on in vitro data, highlighting the need for further investigation.
To address this gap, a leading biotech company leveraged Truveta Data to analyze real-world incidence and prevalence of arrhythmias among patients with epilepsy. The findings provide new insights into ASM-related cardiac risks, helping to inform clinical decision-making and future research.
This case study explores:
- How Truveta Data was used to assess arrhythmia risk in patients with epilepsy
- Key use cases for leveraging clinical notes in research
- The role of real-world data in advancing drug safety research
